259 related articles for article (PubMed ID: 16568458)
1. Metastatic melanoma to lymph nodes in patients with unknown primary sites.
Cormier JN; Xing Y; Feng L; Huang X; Davidson L; Gershenwald JE; Lee JE; Mansfield PF; Ross MI
Cancer; 2006 May; 106(9):2012-20. PubMed ID: 16568458
[TBL] [Abstract][Full Text] [Related]
2. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma.
Lee CC; Faries MB; Wanek LA; Morton DL
J Clin Oncol; 2008 Feb; 26(4):535-41. PubMed ID: 18235114
[TBL] [Abstract][Full Text] [Related]
3. Melanoma without a detectable primary site with metastases to lymph nodes.
Rutkowski P; Nowecki ZI; Dziewirski W; Zdzienicki M; Pieñkowski A; Salamacha M; Michej W; Trepka S; Bylina E; Ruka W
Dermatol Surg; 2010 Jun; 36(6):868-76. PubMed ID: 20482725
[TBL] [Abstract][Full Text] [Related]
4. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
5. Contemporary surgical treatment of advanced-stage melanoma.
Essner R; Lee JH; Wanek LA; Itakura H; Morton DL
Arch Surg; 2004 Sep; 139(9):961-6; discussion 966-7. PubMed ID: 15381613
[TBL] [Abstract][Full Text] [Related]
6. Melanoma of unknown primary origin: a population-based study in the Netherlands.
de Waal AC; Aben KK; van Rossum MM; Kiemeney LA
Eur J Cancer; 2013 Feb; 49(3):676-83. PubMed ID: 23031553
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma.
Galliot-Repkat C; Cailliod R; Trost O; Danino A; Collet E; Lambert D; Vabres P; Dalac S
Eur J Surg Oncol; 2006 Sep; 32(7):790-4. PubMed ID: 16822643
[TBL] [Abstract][Full Text] [Related]
8. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
9. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?
Ballo MT; Garden AS; Myers JN; Lee JE; Diaz EM; Sturgis EM; Morrison WH; Gershenwald JE; Ross MI; Weber RS; Ang KK
Head Neck; 2005 Aug; 27(8):718-21. PubMed ID: 15952196
[TBL] [Abstract][Full Text] [Related]
10. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
11. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
12. Surgery with complete resection improves survival in radiooncologically treated patients with cervical lymph node metastases from cancer of unknown primary.
Hauswald H; Lindel K; Rochet N; Debus J; Harms W
Strahlenther Onkol; 2008 Mar; 184(3):150-6. PubMed ID: 18330511
[TBL] [Abstract][Full Text] [Related]
13. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
14. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
15. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.
Berger AC; Fierro M; Kairys JC; Berd D; Sato T; Andrel J; Hyslop T; Mastrangelo MJ
J Surg Oncol; 2012 Jan; 105(1):15-20. PubMed ID: 21815149
[TBL] [Abstract][Full Text] [Related]
16. The number of lymph nodes involved with metastatic disease does not affect outcome in melanoma patients as long as all disease is confined to the sentinel lymph node.
Jakub JW; Huebner M; Shivers S; Nobo C; Puleo C; Harmsen WS; Reintgen DS
Ann Surg Oncol; 2009 Aug; 16(8):2245-51. PubMed ID: 19517194
[TBL] [Abstract][Full Text] [Related]
17. Vulvar melanoma: a multivariable analysis of 644 patients.
Sugiyama VE; Chan JK; Shin JY; Berek JS; Osann K; Kapp DS
Obstet Gynecol; 2007 Aug; 110(2 Pt 1):296-301. PubMed ID: 17666603
[TBL] [Abstract][Full Text] [Related]
18. [Prognosis after sentinel node biopsy in malignant melanoma].
Lock-Andersen J; Horn J; Sjøstrand H
Ugeskr Laeger; 2006 Jun; 168(25):2457-62. PubMed ID: 16824370
[TBL] [Abstract][Full Text] [Related]
19. Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy.
Tuomaala S; Kivelä T
Ophthalmology; 2004 Apr; 111(4):816-21. PubMed ID: 15051218
[TBL] [Abstract][Full Text] [Related]
20. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
Scheri RP; Essner R; Turner RR; Ye X; Morton DL
Ann Surg Oncol; 2007 Oct; 14(10):2861-6. PubMed ID: 17882497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
